LLY - Eli Lilly and Company - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

LLY is currently covered by 22 analysts with an average price target of $746.09. This is a potential upside of $106.66 (16.68%) from yesterday's end of day stock price of $639.43.

Eli Lilly and Company's activity chart (see below) currently has 515 price targets and 459 ratings on display. The stock rating distribution of LLY is 95.87% BUY and 4.13% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 85% with an average time for these price targets to be met of 246.24 days.

Highest price target for LLY is $1190, Lowest price target is $885, average price target is $969.95.

Most recent stock forecast was given by SEAMUS FERNANDEZ from GUGGENHEIM on 11-Jul-2025. First documented stock forecast 11-Nov-2013.

Currently out of the existing stock ratings of LLY, 116 are a BUY (95.87%), 5 are a HOLD (4.13%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$942

$301.14 (46.99%)

$936

1 months 1 days ago
(11-Jul-2025)

16/20 (80%)

$148.99 (18.79%)

539

Buy

$1135

$494.14 (77.11%)

$1124

1 months 2 days ago
(10-Jul-2025)

29/35 (82.86%)

$344.35 (43.55%)

176

Buy

$1100

$459.14 (71.64%)

$970

5 months 7 days ago
(05-Mar-2025)

13/16 (81.25%)

$170.28 (18.32%)

66

Buy

$1038

$397.14 (61.97%)

$1033

6 months 9 days ago
(03-Feb-2025)

1/4 (25%)

$228.96 (28.30%)

55

Buy

$1190

$549.14 (85.69%)

$1250

6 months 15 days ago
(28-Jan-2025)

0/3 (0%)

$386.39 (48.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is LLY (Eli Lilly and Company) average time for price targets to be met?

On average it took 246.24 days on average for the stock forecasts to be realized with a an average price target met ratio 85

Which analyst has the current highest performing score on LLY (Eli Lilly and Company) with a proven track record?

AKASH TEWARI

Which analyst has the most public recommendations on LLY (Eli Lilly and Company)?

Akash Tewari works at JEFFERIES and has 6 price targets and 5 ratings on LLY

Which analyst is the currently most bullish on LLY (Eli Lilly and Company)?

Peter Verdult with highest potential upside - $549.14

Which analyst is the currently most reserved on LLY (Eli Lilly and Company)?

Florent Cespedes with lowest potential downside - -$566.27

Eli Lilly and Company in the News

Why Eli Lilly Stock Sank 18% This Week

Key Points Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from its upcoming pipeline. The stock is cheaper but still trades at a premium valuation. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly(NYSE: LLY) sank 18% this...

GLP-1 race heats up: Where Eli Lilly stands after weak trial data

Eli Lilly’s (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein senior analyst of US biopharmaceuticals, breaks down what the trial data means for Eli Lilly and the wider pharma space. To watch more expert insights and analysis on the latest market action, check out more Market Domination....
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?